Mckenzi S. Toh
A5088039043- CAR-T cell therapy research
- CRISPR and Genetic Engineering
- T-cell and B-cell Immunology
- Innovation and Socioeconomic Development
- Biosimilars and Bioanalytical Methods
- Genomic variations and chromosomal abnormalities
- Insect symbiosis and bacterial influences
- Cancer Genomics and Diagnostics
- RNA regulation and disease
- Molecular Biology Techniques and Applications
Caribou Biosciences (United States)
2019-2024
Illumina (United States)
2016
Allogeneic chimeric antigen receptor (CAR) T cell therapies hold the potential to overcome many of challenges associated with patient-derived (autologous) CAR cells. Key considerations in development allogeneic include prevention graft-vs-host disease (GvHD) and suppression allograft rejection. Here, we describe preclinical data supporting ongoing first-in-human clinical study, CaMMouflage trial (NCT05722418), evaluating CB-011 patients relapsed/refractory multiple myeloma. is a...
<p>Antitumor activity of CB-011 CAR-T cells in a xenograft model multiple myeloma.</p>
<p>CB-011 immune-cloaking armoring strategy suppresses cytotoxic T and NK cell–mediated allograft rejection.</p>
<p>In vitro serial rechallenge assay demonstrates long-term cytotoxicity activity of CB-011 against BCMA+ tumor cells.</p>
<p>Gamma-secretase inhibitor RO4929097 increases BCMA expression on-target cell lines but does not improve CB-011 antitumor efficacy.</p>
<p>CB-011 cells exhibit in vitro antitumor activity against PBMCs from patients with multiple myeloma.</p>
<div>Abstract<p>Allogeneic chimeric antigen receptor (CAR) T cell therapies hold the potential to overcome many of challenges associated with patient-derived (autologous) CAR cells. Key considerations in development allogeneic include prevention graft-vs-host disease (GvHD) and suppression allograft rejection. Here, we describe preclinical data supporting ongoing first-in-human clinical study, CaMMouflage trial (NCT05722418), evaluating CB-011 patients relapsed/refractory...
<p>CB-011 immune-cloaking armoring strategy reduced NK cell proliferation and CAR+ T stress signatures.</p>
<div>Abstract<p>Allogeneic chimeric antigen receptor (CAR) T cell therapies hold the potential to overcome many of challenges associated with patient-derived (autologous) CAR cells. Key considerations in development allogeneic include prevention graft-vs-host disease (GvHD) and suppression allograft rejection. Here, we describe preclinical data supporting ongoing first-in-human clinical study, CaMMouflage trial (NCT05722418), evaluating CB-011 patients relapsed/refractory...
<p>In vitro serial rechallenge assay demonstrates long-term cytotoxicity activity of CB-011 against BCMA+ tumor cells.</p>
<p>Antitumor activity of CB-011 CAR-T cells in a xenograft model multiple myeloma.</p>
<p>CB-011 immune-cloaking armoring strategy suppresses cytotoxic T and NK cell–mediated allograft rejection.</p>
<p>Antitumor activity of CB-011 CAR-T cells in a xenograft model multiple myeloma.</p>
<p>chRDNA-mediated gene editing did not result in any off-target above the limit of detection.</p>
<p>chRDNA-mediated gene editing did not result in any off-target above the limit of detection.</p>
<p>Gamma-secretase inhibitor RO4929097 increases BCMA expression on-target cell lines but does not improve CB-011 antitumor efficacy.</p>
<p>CB-011 cells exhibit in vitro antitumor activity against PBMCs from patients with multiple myeloma.</p>
<p>Antitumor activity of CB-011 CAR-T cells in a xenograft model multiple myeloma.</p>
<p>CB-011 immune-cloaking armoring strategy reduced NK cell proliferation and CAR+ T stress signatures.</p>
Abstract Background: As our knowledge of how DNA alterations can drive cancer progression increases, assays that simultaneously detect multiple types variants in a simple and cost-effective manner are becoming increasingly crucial. This holds true copy number variations (CNVs), where evaluation this type variant is an important necessary feature any solid tumor profiling assay. Conventional methods for detecting CNVs such as immunohistochemistry (IHC), fluorescence situ hybridization (FISH),...